Welcome to the website of the CTH!

The integrated research and treatment center 'Center for Thrombosis and Haemostasis' (CTH) focuses on the research of the causes and disease mechanisms of thrombosis and blood coagulation diseases. The aim is to continuously improve the diagnosis and treatment of these diseases and to develop effective prophylactic measures. To address this, researchers from basic research and clinical research work closely together in an interdisciplinary manner. At the same time, patients with thrombosis/haemostasis diseases are treated at the CTH Health Care Center, which directly links research and patient treatment.

The CTH was founded in 2010 as part of the national programme "Integrated Research and Treatment Centers (IFB)" funded by the Federal Ministry of Education and Research (BMBF). Within this funding period (2010-2021), the CTH has established itself as an internationally renowned research center in which excellent interdisciplinary cutting-edge research is combined with direct patient care in the field of thrombosis/haemostasis and attractive career paths have been established at the interface of science and clinical practice.
 

On behalf of the CTH, we warmly invite you to to find out about the various tasks and projects of the CTH on our homepage.


Yours,



Professor Stavros Konstantinides, MD (Medical Director CTH)

Professor Wolfram Ruf, MD (Scientific Director CTH)

Dr. Jana Grünewald (General Manager CTH)



Executive Directors (f.l.t.r. Prof. Ruf, Prof. Konstantinides, Dr. Grünewald)
Job advertisements

Press release

Links

Targeted treatment of acute pulmonary embolism

An international study led by Prof. Dr. Stavros Konstantinides, Medical Director of the CTH, shows that high-risk patients with acute pulmonary embolism benefit from an ultrasound-assisted, catheter-based therapy. In this procedure, a thrombolytic drug is delivered directly into the pulmonary arteries. Compared with standard anticoagulation therapy, mortality or life-threatening circulatory collapse decreased by 61 percent. The results were published in the New England Journal of Medicine (March 2026). Press release.

Second funding phase for curATime approved

The cluster for future curATime of TRON gGmbH, University Medical Center Mainz, and DFKI (German Research Center for Artificial Intelligence) is being funded by the Federal Ministry for Research, Technology and Space for a second funding phase. The goal is to develop innovative prevention and therapy solutions for cardiovascular diseases. For the three-year implementation phase, the cluster will receive a total of €15 million in funding. (Feb. 2026). Press release.

curATime funded by the Federal Ministry of Education and Research

curATime - "Cluster for Atherothrombosis and Individualized Medicine" - jointly developed by TRON gGmbH, Mainz University Medical Center and the German Research Center for Artificial Intelligence (DFKI) is now one of the clusters of the "Clusters4Future" initiative of the German Federal Ministry of Education and Research (BMBF). For the first, three-year implementation phase, curATime will receive funding totaling 15 million euros. (July 2022) Press release.